Abstract Details

Title Paraoxonase1 (An Antioxidant): A Marker of Treatment Response in Multiple Sclerosis?

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 246

Objective

Background BACKGROUND: Paraoxonase1 (PON1), an enzyme associated with high density lipoprotein (HDL), plays an important role in the anti-oxidant and anti-inflammatory properties of HDL. The aim of this study was to investigate the activity of PON1 in patients with different types of MS and with different treatment.

Design/Methods DESIGN/METHODS: 197 MS patients were included. PON1 and arylesterase activities of the serum were measured spectrophotometrically. The activities of PON1 and lipid profiles were compared in subgroups of relapsing-remitting (134), benign (15), primary progressive (12), secondary progressive (19), relapsing progressive (4) and clinically isolated syndrome (13), at different stages of the disease (EDSS: group A: 0-4.0; group B: 4.5-6.5; group C: >6.5) and in subgroups according to the type of IMT or response to the treatment.

Results RESULTS: The means of serum PON1-paraoxonase and arylesterase activity were 141+/- 106 unit/L and 127 +/- 27 unit/mL, respectively. PON1 activity did not differ in the subgroups regarding of the course of MS. PON1 activity had a tendency to be higher in patients with higher EDSS. Patients with greater disability were older and had slightly lower, but statistically not significant HDL blood levels than those of less disabled. PON1 activities were different in the groups according to the treatment type (p=0.0002) and the therapeutic response (p=0.0216).

Conclusions CONCLUSIONS: Our results did not demonstrate association between altered lipoprotein peroxidation and different clinical types of MS, but PON1 activity might be a useful marker in monitoring the response to immunomodulatory treatment.

Authors/Disclosures
Tunde Csepany, MD (University of Debrecen) PRESENTER	Dr. Csepany has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jeffrey M. Gelfand, MD, MS, FAAN (University of California, San Francisco)	Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.

��ɫ��

��ɫ��